Beacon developing saliva-based cancer tests under agreement with Centocor.
This article was originally published in The Gray Sheet
Executive SummaryBEACON DIAGNOSTICS SALIVA-BASED GASTROINTESTINAL CANCER TEST 510(k) is slated for submission to FDA in early 1998, the company says. The GI kit is the first product expected to come to market under an exclusive worldwide licensing agreement between Beacon and Centocor covering tumor detection technology.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.